RGD Reference Report - By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke. - Rat Genome Database
Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke.

Authors: Li, S  Wu, C  Zhu, L  Gao, J  Fang, J  Li, D  Fu, M  Liang, R  Wang, L  Cheng, M  Yang, H 
Citation: Li S, etal., Molecules. 2012 Nov 9;17(11):13403-23. doi: 10.3390/molecules171113403.
RGD ID: 10054501
Pubmed: (View Article at PubMed) PMID:23143152
DOI: Full-text: DOI:10.3390/molecules171113403

Ischemic stroke is a devastating disease with a complex pathophysiology. Galangin is a natural flavonoid isolated from the rhizome of Alpina officinarum Hance, which has been widely used as an antioxidant agent. However, its effects against ischemic stroke have not been reported and its related neuroprotective mechanism has not really been explored. In this study, neurological behavior, cerebral infarct volumes and the improvement of the regional cortical blood flow (rCBF) were used to evaluate the therapeutic effect of galangin in rats impaired by middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia. Furthermore, the determination of mitochondrial function and Western blot of apoptosis-related proteins were performed to interpret the neuroprotective mechanism of galangin. The results showed that galangin alleviated the neurologic impairments, reduced cerebral infarct at 24 h after MCAO and exerted a protective effect on the mitochondria with decreased production of mitochondrial reactive oxygen species (ROS). These effects were consistent with improvements in the membrane potential level (Dym), membrane fluidity, and degree of mitochondrial swelling in a dose-dependent manner. Moreover, galangin significantly improved the reduced rCBF after MCAO. Western blot analysis revealed that galangin also inhibited apoptosis in a dose-dependent manner concomitant with the up-regulation of Bcl-2 expression, down-regulation of Bax expression and the Bax/Bcl-2 ratio, a reduction in cytochrome c release from the mitochondria to the cytosol, the reduced expression of activated caspase-3 and the cleavage of poly(ADP-ribose) polymerase (PARP). All these data in this study demonstrated that galangin might have therapeutic potential for ischemic stroke and play its protective role through the improvement in rCBF, mitochondrial protection and inhibiting caspase-dependent mitochondrial cell death pathway for the first time.

Annotation

Disease Annotations    

Objects Annotated

Genes (Rattus norvegicus)
Bax  (BCL2 associated X, apoptosis regulator)
Bcl2  (BCL2, apoptosis regulator)
Casp3  (caspase 3)
Parp1  (poly (ADP-ribose) polymerase 1)

Genes (Mus musculus)
Bax  (BCL2-associated X protein)
Bcl2  (B cell leukemia/lymphoma 2)
Casp3  (caspase 3)
Parp1  (poly (ADP-ribose) polymerase family, member 1)

Genes (Homo sapiens)
BAX  (BCL2 associated X, apoptosis regulator)
BCL2  (BCL2 apoptosis regulator)
CASP3  (caspase 3)
PARP1  (poly(ADP-ribose) polymerase 1)


Additional Information